Search Results
Aug 11, 2026, 08:00 ET Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes,1 following the U.S. Food and Drug Administration (FDA) approval earlier this year."Awiqli® represents meaningful progress in the options available for basal insulin
More news about: Novo Nordisk
Aug 11, 2026, 07:50 ET SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).
the discovery and development of groundbreaking new medicines for disorders related to the central nervous system (CNS). With a proven track record of drug development and commercialization, Neurim's first products, Circadin® and Slenyto®, are already in use in more than 40 countries across 5 continents.
More news about: Kye Pharmaceuticals Inc.
Aug 11, 2026, 07:30 ET Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
skin irritation near the tumor site. In March 2026, a protocol amendment was approved by the Swissmedic and the Swiss Ethics Committee to use a lower drug volume per tumor volume ratio and a single injection of INT230-6 in Cohort A. In August 2026, the Company opened its first site in France for accrual
More news about: Intensity Therapeutics Inc.
Aug 11, 2026, 07:00 ET RazorMetrics Named to Inc. 5000 Fastest-Growing Companies List for Second Consecutive Year
strong growth driven by increasing demand from health plans, employers, PBMs, and other organizations seeking practical ways to reduce prescription drug spend without placing more burden on patients or disrupting provider workflows."Being named to the Inc. 5000 for a second consecutive year is
More news about: RazorMetrics
Aug 11, 2026, 07:00 ET Transpire Bio's Dr. Lei Mao Appointed as Board Chair of the IPAC-RS for its 2026-2028 Term
election reflects both his individual and scientific expertise and highlights Transpire Bio's position as a global thought leader in inhalation and inhaled drug-device combination products. We believe engagement with organizations such as IPAC-RS is important in shaping the scientific and regulatory environment
More news about: Transpire Bio
Aug 11, 2026, 06:30 ET Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
which was related to non-cash stock compensation, (ii) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing, (iii) a $3.1 million increase for vidofludimus calcium drug supply and (iv) a $1.3 million increase related to costs across numerous categories, partially
More news about: Immunic, Inc.
Aug 11, 2026, 06:30 ET CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and Subsequent Capital RaiseOn
More news about: Hagens Berman Sobol Shapiro LLP
Aug 11, 2026, 06:00 ET Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.With over 45 years of experience and a
More news about: Cambrex
Aug 11, 2026, 06:00 ET Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.With over 45 years of experience and a
More news about: Cambrex
Aug 11, 2026, 05:45 ET Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30, 2026 and provide
More news about: Insilico Medicine
Aug 11, 2026, 02:57 ET Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
https://www.cancer.org/cancer/bladder-cancer.html About Hexvix®/Cysview® (hexaminolevulinate HCl)Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with
More news about: Photocure
Aug 11, 2026, 02:52 ET Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
https://www.cancer.org/cancer/bladder-cancer.html About Hexvix®/Cysview® (hexaminolevulinate HCl)Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with
More news about: Photocure
Aug 10, 2026, 21:30 ET Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
models do not just solve individual drug discovery tasks; they learn the rules of biology, to understand, generate, predict and intervene in complex biological systems.As foundation models and automated R&D converge, Aureka is shifting from using AI to make drug discovery more efficient to using
More news about: Aureka
Aug 10, 2026, 18:01 ET REPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit
2025, Replimune allegedly published a press release announcing that the U.S. Food and Drug Administration ("FDA") had accepted the resubmission of the Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment
More news about: Robbins Geller Rudman & Dowd LLP
Aug 10, 2026, 16:05 ET Immunic Appoints Elena Ridloff to Board of Directors
the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of
More news about: Immunic, Inc.
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation
More news about: Biohaven Ltd.
Aug 10, 2026, 12:00 ET Former federal data officials answer the question: How many federal datasets have been terminated since January 2025?
Director of the Data Policy Institute at the Federation of American Scientists. "The termination of federal data – whether related to food security, drug abuse, or hate crimes – has far reaching impacts. Many of these terminations occurred behind closed doors and without opportunity for public input,
More news about: dataindex.us
Aug 10, 2026, 11:48 ET Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
(NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.
More news about: Lupin Pharmaceuticals, Inc.
Aug 10, 2026, 10:31 ET Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
ALTO-300 is a small-molecule therapy with melatonergic agonist and serotonergic antagonist properties that enhances dopamine and norepinephrine activity. The drug is being developed in the United States as an adjunctive treatment for MDD in patients identified through EEG biomarker profiling. Although ALTO-300
More news about: DelveInsight Business Research, LLP
Aug 10, 2026, 10:01 ET Ventilators Market worth $3.10 billion by 2031 - Exclusive Report by MarketsandMarkets™
Respiratory Care Devices Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets
Aug 10, 2026, 10:00 ET REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group, Inc.
Jr., or call Robbins LLP at (800) 350-6003.Why Was Replimune Sued? On October 20, 2025, Replimune announced that the U.S. Food and Drug Administration ("FDA") had accepted the resubmission of the Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment
More news about: Robbins LLP
Aug 10, 2026, 09:30 ET Access Insights Conference 2026 Surges Toward Sellout as Biopharma Leaders Race to Secure Seats
Registration is filling fast for biopharma's only conference dedicated to the full spectrum of drug commercialization, taking place October 19–21 at the Mayflower Hotel in Washington, D.C.PHILADELPHIA, Aug. 10, 2026
More news about: IntegriChain, Inc.
Aug 10, 2026, 09:28 ET BEING FRENSHE EXPANDS INTO CANADA, MARKING THE BRAND'S FIRST INTERNATIONAL RETAIL EXPANSION
the wellness brand founded by Ashley Tisdale and developed in partnership with Maesa, announced on Saturday August 8 the brand's launch at Shoppers Drug Mart, one of the most recognized and trusted names in Canadian retailing, providing pharmacy services, health and wellness products, beauty offerings
More news about: Being Frenshe
Aug 10, 2026, 09:15 ET Jif® Unveils First Major Brand Refresh in More than 30 Years as Peanut Butter Moves Beyond the PB&J
to The J.M. Smucker Co. for packaged coffee products sold in retail channels, such as grocery stores, mass merchandisers, club stores, e-commerce and drug stores, as well as in certain away from home channels. This information does not pertain to products for sale in Dunkin'® restaurants.
More news about: The J.M. Smucker Co.
Aug 10, 2026, 09:05 ET BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound
More news about: BioMarin Pharmaceutical Inc.